Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK42360 in Pediatric BRAF V600-Mutant Malignant Brain Tumors
NCT07158710Phase 1Recruiting
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Aug 2025
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HSK42360 in brain tumor (2 arms), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoints: Maximum Tolerated Dose, Dose-Limiting Toxicities and 3 more. Started Aug 2025; status: recruiting.
02
Drugs
HSK42360
03
Conditions
brain tumor
Beyond the preview
Go deeper on NCT07158710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07158710.